Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. It uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The Company’s SMDCs actively target receptors that are over-expressed on diseased cells relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment.


Type
Public
HQ
West Lafayette, US
Founded
1995
Size (employees)
76 (est)
Endocyte was founded in 1995 and is headquartered in West Lafayette, US
Report incorrect company information

Key People/Management at Endocyte

Mike A. Sherman

Mike A. Sherman

President & CEO

Endocyte Office Locations

Endocyte has offices in Indianapolis and West Lafayette
West Lafayette, US (HQ)
3000 Kent Avenue
Indianapolis, US
8910 Purdue Rd, Suite 250
Show all (2)
Report incorrect company information

Endocyte Financials and Metrics

Endocyte Financials

Endocyte's revenue was reported to be $70 k in FY, 2017
USD

Revenue (Q1, 2018)

15.9 k

Net income (Q1, 2018)

(8.6 m)

EBIT (Q1, 2018)

(9 m)

Market capitalization (23-May-2018)

973.7 m

Closing share price (23-May-2018)

14
Endocyte's current market capitalization is $973.7 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

64.9 m70.4 m70 k70 k70 k

Revenue growth, %

8%(100%)

General and administrative expense

17.3 m13.8 m

R&D expense

27.5 m25.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

17.3 m12.5 k12.5 k12.5 k32.5 k12.5 k12.5 k15.9 k

General and administrative expense

6.1 m7.5 m8 m4 m4.4 m4.1 m3.8 m3.8 m7.4 m3 m3.7 m3.3 m3.8 m

R&D expense

13.5 m13 m19 m5.7 m6.6 m6.7 m6.6 m6.5 m6.8 m6 m8 m8.7 m5.3 m

Operating expense total

19.6 m20.5 m27 m9.7 m11 m10.8 m10.4 m10.4 m14.2 m9 m11.7 m12 m9 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

52.8 m45.5 m15.4 m31.2 m

Accounts Receivable

273 k

Inventories

Current Assets

133.3 m127 m174.9 m140.3 m98.6 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2018

Cash

51.2 m32.9 m31.6 m48.6 m29.2 m28 m31 m40.2 m26.6 m34.7 m

Current Assets

123.9 m135 m128.7 m134.3 m162.2 m175 m173.7 m164.8 m155.8 m148.5 m174.6 m

PP&E

3.4 m3.9 m4.2 m4.1 m3.8 m3.7 m3.6 m3.6 m3.5 m3.4 m1.9 m

Total Assets

175.6 m146.5 m230.9 m221 m202.6 m194 m185.6 m168.5 m159.4 m152 m176.7 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(18 m)5.5 m(41.3 m)(43.9 m)

Depreciation and Amortization

674.7 k857.1 k886.7 k

Accounts Payable

(386.2 k)(3.7 m)(60.7 k)1.4 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(3 m)(3.1 m)22.4 m(5.7 m)(10.9 m)(10.6 m)(10 m)(10.2 m)(24.1 m)(32.8 m)(11.5 m)

Depreciation and Amortization

444.4 k679.7 k

Accounts Payable

3.5 m1.1 m1.6 m1.5 m956.9 k1.2 m(219.1 k)104.1 k1.5 m1.2 m

Cash From Operating Activities

(18.5 m)(26.1 m)
USDY, 2018

Financial Leverage

1 x
Show all financial metrics
Report incorrect company information